What is Sava?
Sava is at the forefront of redefining personal health interaction through advanced biosensing technology. The company's innovative approach aims to provide real-time, painless, and affordable access to crucial bodily information, positioning itself as a leader in the health tech industry. By focusing on non-invasive data collection, Sava is poised to empower individuals with greater control and understanding of their well-being.
How much funding has Sava raised?
Sava has raised a total of $27M across 2 funding rounds:
Angel/Seed
$8M
Series A
$19M
Angel/Seed (2024): $8M with participation from Balderton and EXOR
Series A (2025): $19M led by True Capital, JamJar Investments, Norrsken Vc, Balderton, Athletico Ventures, Italian Founders Fund, and Exceptional Ventures
Key Investors in Sava
Balderton
Balderton Capital is a prominent European venture capital firm specializing in early-stage, high-growth technology companies, often leading Seed and Series A rounds.
EXOR
Exor is a global investment holding company with diverse interests, including technology and automotive sectors, making medium to long-term investments.
True Capital
True Capital Limited is an advisory and investment firm focused on the consumer and tech industries, fostering collaboration between established companies and startups.
What's next for Sava?
With a substantial enterprise-level funding context and a recent strategic investment, Sava is well-positioned for scaling its operations and further developing its groundbreaking biosensing technology. The company's trajectory suggests a move towards broader market penetration and potential expansion into new health monitoring applications. Future developments will likely focus on leveraging this capital to enhance product capabilities, expand research and development, and solidify its market presence.
See full Sava company page
